Statutory Profit Doesn't Reflect How Good Phibro Animal Health's (NASDAQ:PAHC) Earnings Are
May 15
Have your own idea? Try our Stock Screener
U.S. Pharma Industry Analysis
UpdatedMay 15, 2025
DataAggregated Company Financials
Companies301
- 7D-6.3%
- 3M-13.7%
- 1Y-14.7%
- YTD-10.2%
Over the last 7 days, the Pharma industry has dropped 6.3%, driven by Eli Lilly declining 7.9%. In contrast, Regencell Bioscience Holdings has gained 81%. The industry has fallen 15% in the last year. Looking forward, earnings are forecast to grow by 15% annually.
Industry Valuation and Performance
Has the U.S. Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 15 May 2025 | US$1.7t | US$382.6b | US$61.1b | 16.6x | 27.1x | 4.3x |
| Sat, 12 Apr 2025 | US$1.6t | US$380.0b | US$40.6b | 15.5x | 39.6x | 4.2x |
| Mon, 10 Mar 2025 | US$1.9t | US$381.1b | US$39.2b | 16.5x | 49.1x | 5.1x |
| Wed, 05 Feb 2025 | US$1.9t | US$375.6b | US$38.5b | 18.3x | 48x | 4.9x |
| Fri, 03 Jan 2025 | US$1.8t | US$369.3b | US$31.3b | 16.5x | 57.1x | 4.8x |
| Sun, 01 Dec 2024 | US$1.9t | US$373.8b | US$30.6b | 19.4x | 61x | 5x |
| Tue, 29 Oct 2024 | US$2.0t | US$365.3b | US$23.7b | 18.1x | 83.2x | 5.4x |
| Thu, 26 Sep 2024 | US$2.0t | US$364.2b | US$25.3b | 18.4x | 80.3x | 5.6x |
| Sat, 24 Aug 2024 | US$2.0t | US$362.1b | US$21.8b | 17.9x | 93.7x | 5.6x |
| Mon, 22 Jul 2024 | US$2.0t | US$356.5b | US$13.1b | 15.9x | 149.1x | 5.5x |
| Wed, 19 Jun 2024 | US$1.9t | US$358.3b | US$14.1b | 15.5x | 137.3x | 5.4x |
| Fri, 17 May 2024 | US$1.9t | US$358.3b | US$14.0b | 18.3x | 134.9x | 5.3x |
| Sun, 14 Apr 2024 | US$1.8t | US$355.1b | US$23.9b | 21.4x | 76.5x | 5.2x |
| Tue, 12 Mar 2024 | US$1.9t | US$355.3b | US$22.4b | 22.4x | 83.2x | 5.2x |
| Thu, 08 Feb 2024 | US$1.8t | US$354.8b | US$23.1b | 28.5x | 79.4x | 5.2x |
| Sat, 06 Jan 2024 | US$1.7t | US$375.2b | US$33.8b | 27.5x | 51.7x | 4.7x |
| Mon, 04 Dec 2023 | US$1.7t | US$375.2b | US$33.9b | 27.2x | 48.7x | 4.4x |
| Wed, 01 Nov 2023 | US$1.6t | US$383.5b | US$46.5b | 13.6x | 34.3x | 4.2x |
| Fri, 29 Sep 2023 | US$1.7t | US$381.8b | US$43.7b | 18.5x | 37.8x | 4.3x |
| Sun, 27 Aug 2023 | US$1.8t | US$381.6b | US$44.1b | 20.5x | 40.2x | 4.6x |
| Tue, 25 Jul 2023 | US$1.7t | US$394.3b | US$60.5b | 18.6x | 28.6x | 4.4x |
| Thu, 22 Jun 2023 | US$1.7t | US$392.8b | US$60.1b | 18.9x | 29x | 4.4x |
| Sat, 20 May 2023 | US$1.7t | US$392.9b | US$60.5b | 19.1x | 28.5x | 4.4x |
| Mon, 17 Apr 2023 | US$1.7t | US$401.3b | US$68.5b | 17.5x | 24.3x | 4.2x |
| Wed, 15 Mar 2023 | US$1.5t | US$401.1b | US$69.3b | 16.6x | 22.3x | 3.9x |
| Fri, 10 Feb 2023 | US$1.6t | US$401.8b | US$68.8b | 18x | 23.9x | 4.1x |
| Sun, 08 Jan 2023 | US$1.8t | US$403.7b | US$70.7b | 17.5x | 25x | 4.4x |
| Tue, 06 Dec 2022 | US$1.8t | US$403.7b | US$70.7b | 17x | 25.2x | 4.4x |
| Thu, 03 Nov 2022 | US$1.7t | US$403.6b | US$71.6b | 16.1x | 23.4x | 4.2x |
| Sat, 01 Oct 2022 | US$1.6t | US$403.0b | US$71.3b | 12.4x | 21.9x | 3.9x |
| Mon, 29 Aug 2022 | US$1.6t | US$402.9b | US$70.2b | 14.7x | 22.9x | 4x |
| Wed, 27 Jul 2022 | US$1.7t | US$393.1b | US$63.5b | 22.6x | 26.4x | 4.3x |
| Fri, 24 Jun 2022 | US$1.7t | US$392.6b | US$64.9b | 21.4x | 25.7x | 4.3x |
| Sun, 22 May 2022 | US$1.7t | US$392.5b | US$64.7b | 20.1x | 25.8x | 4.2x |
Price to Earnings Ratio
25.8x
Current Industry PE
- Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 27.1x which is lower than its 3-year average PE of 51.9x.
- The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
- Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
- This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 5.09% | |
| Healthcare | -4.10% | |
| Pharma | -6.29% | |
| Pharma | -6.29% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RGC Regencell Bioscience Holdings | US$342.99 | 80.5% +US$2.0b | 6,485.8% | PB543.1x | |
| ELAN Elanco Animal Health | US$12.88 | 7.2% +US$432.1m | -24.4% | PE17.1x | |
| JAZZ Jazz Pharmaceuticals | US$106.59 | 5.1% +US$317.4m | -2.9% | PE13.6x | |
| LQDA Liquidia | US$18.65 | 21.5% +US$282.1m | 46.4% | PS112.7x | |
| PBH Prestige Consumer Healthcare | US$85.40 | 4.9% +US$187.1m | 28.5% | PE19.7x |